PFIZER INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PFIZER INC (PFE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $288.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $289.00M, a 26.09% decline year-over-year.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-10-02 was $221.00M, a 36.49% decline year-over-year.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $391.00M, a 54.55% increase year-over-year.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-10-03 was $348.00M, a 319.28% increase year-over-year.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $288.00M, a 1.77% increase from fiscal 2024.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $283.00M, a 53.91% decline from fiscal 2023.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $614.00M, a 18.35% decline from fiscal 2022.
- PFIZER INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $752.00M, a 61.30% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $288.00M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $283.00M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $614.00M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $289.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $510.00M derived: sum of 2 quarters · filed 2025-02-27 | $752.00M 10-K · filed 2025-02-27 | ||
| 2022-10-02 | $221.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $463.00M 10-Q · filed 2022-11-09 | |||
| 2022-07-03 | $242.00M 10-Q · filed 2022-08-10 | ||||
| 2021-12-31 | $391.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $739.00M derived: sum of 2 quarters · filed 2024-02-22 | $1.94B 10-K · filed 2024-02-22 | ||
| 2021-10-03 | $348.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.55B 10-Q · filed 2022-11-09 | |||
| 2021-07-04 | $1.20B 10-Q · filed 2022-08-10 | ||||
| 2020-12-31 | $253.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $336.00M derived: sum of 2 quarters · filed 2023-02-23 | $410.00M 10-K · filed 2023-02-23 | $413.00M 10-K · filed 2021-02-25 | |
| 2020-09-27 | $83.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $157.00M 10-Q · filed 2021-11-12 | |||
| 2020-06-28 | $74.00M 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $64.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $192.00M derived: sum of 2 quarters · filed 2022-02-24 | $268.00M derived: sum of 3 quarters · filed 2022-02-24 | $314.00M 10-K · filed 2022-02-24 | $326.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | $128.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $204.00M derived: sum of 2 quarters · filed 2019-11-07 | $250.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $122.00M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $46.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |